Hetero Labs Limited FDA Inspection Record
Hetero Labs Limited is an FDA-registered facility (FEI 3008307735) located in Mahabubnagar, IN. Registered operations: MANUFACTURE. RegDataLab tracks 5 FDA inspections and 1 compliance action at this facility.
What FDA found at this site
- Latest inspection
- Aug 12, 2022: Voluntary Action Indicated (VAI)
- Inspections on record
- 5 (1 OAI, 2 VAI, 2 NAI)
- Last OAI inspection
- Dec 16, 2016
- Warning letters
- 1 listed by FDA for this FEI, latest Aug 15, 2017
- Form 483 and inspection documents
- 1 in FDA's reading room
- Recalls as the recalling firm
- 7, latest Mar 26, 2026
- Import refusals
- 4
Inspections and what FDA cited
| Date | Result | What FDA cited |
|---|---|---|
| Aug 12, 2022 | Voluntary Action Indicated (VAI) | Procedures not in writing, fully followed (21 CFR 211.22(d)) Training , Education , Experience overall (21 CFR 211.25(a)) Written procedures not established/followed (21 CFR 211.67(b)) Computer control of master formula records (21 CFR 211.68(b)) and 2 more |
| Dec 16, 2016 | Official Action Indicated (OAI) | No citations listed |
| May 1, 2015 | No Action Indicated (NAI) | No citations listed |
| May 24, 2013 | Voluntary Action Indicated (VAI) | No citations listed |
| Nov 19, 2010 | No Action Indicated (NAI) | No citations listed |
Recalls
| Date | Class | Recall | Product and reason |
|---|---|---|---|
| Mar 26, 2026 | Class II | D-0484-2026 | Pantoprazole Sodium, Delayed-Release Tablets, USP, 40 mg, 1000-count bottle, Rx only… Discoloration: Firm received five (5) complaints stating that, "Tablets discolored darker than normal and have lighter-colored spots." |
| Aug 6, 2020 | Class II | D-1545-2020 | Losartan Potassium Tablets USP, 50 mg, 90 count bottles, Rx only, Manufactured for: Camber… Failed Tablet/Capsule Specification; complaint of bulging tablet |
| Aug 20, 2018 | Class II | D-1213-2018 | Montelukast Sodium Tablets, 10 mg*, 30-count bottles, Rx Only, By: Hetero, Hetero Labs… Discoloration: A complaint was received from a pharmacist for the presence of blue specks on tablets. |
| Aug 15, 2018 | Class I | D-0081-2019 | Montelukast Sodium Tablets 10 mg, 30-count bottle, Rx Only, By: Hetero Hetero Labs… Labeling: Label Mix-Up - One lot labeled Montelukast Sodium Tablets 10 mg tablets may contain 90 tablets of Losartan Potassium 50 mg. |
| Aug 8, 2018 | Class II | D-1113-2018 | Camber Pharmaceuticals, Inc. Valsartan Tablets, USP, 40 mg, 30 Tablets Rx Only… and 3 more products CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. |
| Feb 13, 2018 | Class II | D-0601-2018 | Valganciclovir Tablets, USP, 450 mg, 60-count bottle, Rx Only,
Manufactured for Camber… and 1 more product Temperature Abuse: Valganciclovir Tablets USP 450 mg and Valacyclovir Tablets USP 1 gram were exposed to higher temperature at airport or… |
| Dec 22, 2017 | Class II | D-0415-2018 | Famciclovir Tablets, 500 mg, 30-count bottles, Rx Only, Manufactured For: Camber… Temperature Abuse: Complaints of tablets being wet and stuck together with tablet coating peeled and disintegrated as a result of prolonged… |
Form 483s and inspection documents
FDA record score
31 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. Each record below adds the points shown.
11 records behind this number
| Record | Date | Points x age weight | Adds |
|---|---|---|---|
| Warning letter on FDA's dashboard, which does not show close-outs | Aug 15, 2017 | 30 x 0.25 | 7.5 |
| Inspection classified OAI | Dec 16, 2016 | 30 x 0.25 | 7.5 |
| Class II recall D-0484-2026, this FEI as the recalling firm | Mar 26, 2026 | 4 x 1 | 4 |
| Class I recall D-0081-2019, this FEI as the recalling firm | Aug 15, 2018 | 15 x 0.25 | 3.8 |
| Inspection classified VAI | Aug 12, 2022 | 6 x 0.6 | 3.6 |
| Class II recall D-1545-2020, this FEI as the recalling firm | Aug 6, 2020 | 4 x 0.25 | 1 |
| Class II recall D-1213-2018, this FEI as the recalling firm | Aug 20, 2018 | 4 x 0.25 | 1 |
| Class II recall D-1113-2018, this FEI as the recalling firm | Aug 8, 2018 | 4 x 0.25 | 1 |
| Class II recall D-0601-2018, this FEI as the recalling firm | Feb 13, 2018 | 4 x 0.25 | 1 |
| Class II recall D-0415-2018, this FEI as the recalling firm | Dec 22, 2017 | 4 x 0.25 | 1 |
| Inspection classified VAI | May 24, 2013 | 10 years or older, so it adds no points | 0 |
When each source was last refreshed
| Records | Last refreshed | Source as of | Status |
|---|---|---|---|
| Inspections | Nov 17, 2026 | Newest record Nov 9, 2026 | Current |
| Inspection citations | Nov 17, 2026 | Newest record Nov 5, 2026 | Current |
| Compliance actions (warning letters, injunctions and other action types) | Nov 2, 2026 | Newest record Oct 29, 2026 | Current |
| Warning letter text | Nov 17, 2026 | Newest record Nov 10, 2026 | Current |
| Recalls (Enforcement Report) | Nov 17, 2026 | Newest record Nov 11, 2026 | Current |
| Form 483s and inspection documents | Nov 17, 2026 | Newest record Nov 16, 2026 | Current |
| Import refusals | Nov 15, 2026 | Newest record Nov 5, 2026 | Current |
Reviewing Hetero Labs Limited as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.
Or check Hetero Labs Limited yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.
Facility details
- Company
- Hetero Labs Limited (Unit V)
- Location
- Mahabubnagar (IN)
- Registration Expires
- Dec 31, 2027
- Operations
- MANUFACTURE
- Source
- decrs